-
CHMP highlights: June 2022
CHMP highlights: June 2022
-
CHMP highlights: June 2022
CHMP highlights: June 2022
EMA's human medicines committee (CHMP) recommended 9 new medicines for approval in the EU at its June 2022 meeting
-
Valneva recommended for authorisation in the EU
Valneva recommended for authorisation in the EU
-
Valneva recommended for authorisation in the EU
Valneva recommended for authorisation in the EU
EMA recommended granting a marketing authorisation for COVID-19 Vaccine Valneva, to use in people aged 18 to 50 years as their primary vaccination
-
Nuvaxovid recommended for adolescents in the EU
Nuvaxovid recommended for adolescents in the EU
-
Nuvaxovid recommended for adolescents in the EU
Nuvaxovid recommended for adolescents in the EU
EMA recommended the use of Novavax’s COVID-19 vaccine, Nuvaxovid, in adolescents aged 12 to 17 years
-
Management Board: Highlights of June meeting
Management Board: Highlights of June meeting
-
Management Board: Highlights of June meeting
Management Board: Highlights of June meeting
The Board elected a new vice-chair and was updated on COVID-19 related activities, EMA’s extended mandate, Clinical Trials in the EU and progress of many other projects
Information for you
Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal